The WHO CNS 5th Edition: A Quandary for the Surgical Neurooncologist and Adult Diffuse Glioma Patients in LMICs

CC BY 4.0 · Indian Journal of Neurosurgery 2023; 12(02): 093-094
DOI: 10.1055/s-0043-1771473

Editorial

James A. Balogun

¹Division of Neurosurgery, Department of Surgery, College of Medicine, University of Ibadan/ University College Hospital, Ibadan, Nigeria

References
1 Louis DN, Perry A, Wesseling P. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncol 2021; 23 (08) 1231-1251
2 Molinaro AM, Hervey-Jumper S, Morshed RA. et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol 2020; 6 (04) 495-503
3 Sharma S, Mathur K, Mittal A, Mukta M, Jindal A, Kumar M. Study of surrogate immunohistochemical markers IDH1, ATRX, BRAF V600E, and p53 mutation in astrocytic and oligodendroglial tumors. Ind J Neurosurg 2022; 12 (02) 135-144
4 Santosh V, Sravya P, Gupta T. et al. ISNO consensus guidelines for practical adaptation of the WHO 2016 classification of adult diffuse gliomas. Neurol India 2019; 67 (01) 173-182